High–titer selective serum anti–β–tubulin antibodies in chronic inflammatory demyelinating polyneuropathy

A. M. Connolly, Alan Pestronk, J. L. Trotter, E. L. Feldman, David Cornblath, R. K. Olney

Research output: Contribution to journalArticle

Abstract

Although chronic inflammatory demyelinating polyneuropathy (CIDP) is presumed to be an autoimmune disorder, no neural antigen has been recognized as an immune target. We found that serum IgM from a patient with CIDP and an IgM paraprotein reacted with a 53-kd protein by Western blot analysis. Amino acid sequence analysis identified this protein as β-tubulin. We then studied sera from 70 CIDP patients, 35 Guillain-Barré syndrome (GBS) patients, and 483 disease (amyotrophic lateral sclerosis, Alzheimer's disease, multiple sclerosis, diabetes, and other polyneuropathies) and normal controls for selective high-titer anti-β-tubulin using ELISA methodology. Forty-two percent (30/70) of patients with CIDP had selective high titer IgM reactivity against β-tubulin; 23% (16/70) had selective high-titer IgG reactivity against β-tubulin. Overall, 57% of CIDP patients, 20% of GBS patients, and 2% of control patients had selective, high serum IgM or IgG anti-β-tubulin reactivity. Selective high-titer serum anti-β-tubulin antibodies occur in a majority of patients with CIDP but are rare in other chronic neuropathies or CNS disorders.

Original languageEnglish (US)
Pages (from-to)557-562
Number of pages6
JournalNeurology
Volume43
Issue number3
StatePublished - 1993

Fingerprint

Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Tubulin
Antibodies
Serum
Immunoglobulin M
Paraproteins
Polyneuropathies
Protein Sequence Analysis
Amyotrophic Lateral Sclerosis
Multiple Sclerosis
Anti-Idiotypic Antibodies
Alzheimer Disease
Proteins
Immunoglobulin G
Western Blotting
Enzyme-Linked Immunosorbent Assay
Antigens

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology
  • Neuroscience(all)

Cite this

Connolly, A. M., Pestronk, A., Trotter, J. L., Feldman, E. L., Cornblath, D., & Olney, R. K. (1993). High–titer selective serum anti–β–tubulin antibodies in chronic inflammatory demyelinating polyneuropathy. Neurology, 43(3), 557-562.

High–titer selective serum anti–β–tubulin antibodies in chronic inflammatory demyelinating polyneuropathy. / Connolly, A. M.; Pestronk, Alan; Trotter, J. L.; Feldman, E. L.; Cornblath, David; Olney, R. K.

In: Neurology, Vol. 43, No. 3, 1993, p. 557-562.

Research output: Contribution to journalArticle

Connolly, AM, Pestronk, A, Trotter, JL, Feldman, EL, Cornblath, D & Olney, RK 1993, 'High–titer selective serum anti–β–tubulin antibodies in chronic inflammatory demyelinating polyneuropathy', Neurology, vol. 43, no. 3, pp. 557-562.
Connolly, A. M. ; Pestronk, Alan ; Trotter, J. L. ; Feldman, E. L. ; Cornblath, David ; Olney, R. K. / High–titer selective serum anti–β–tubulin antibodies in chronic inflammatory demyelinating polyneuropathy. In: Neurology. 1993 ; Vol. 43, No. 3. pp. 557-562.
@article{7545fdda8fdc4170aeebb0699015f6f7,
title = "High–titer selective serum anti–β–tubulin antibodies in chronic inflammatory demyelinating polyneuropathy",
abstract = "Although chronic inflammatory demyelinating polyneuropathy (CIDP) is presumed to be an autoimmune disorder, no neural antigen has been recognized as an immune target. We found that serum IgM from a patient with CIDP and an IgM paraprotein reacted with a 53-kd protein by Western blot analysis. Amino acid sequence analysis identified this protein as β-tubulin. We then studied sera from 70 CIDP patients, 35 Guillain-Barr{\'e} syndrome (GBS) patients, and 483 disease (amyotrophic lateral sclerosis, Alzheimer's disease, multiple sclerosis, diabetes, and other polyneuropathies) and normal controls for selective high-titer anti-β-tubulin using ELISA methodology. Forty-two percent (30/70) of patients with CIDP had selective high titer IgM reactivity against β-tubulin; 23{\%} (16/70) had selective high-titer IgG reactivity against β-tubulin. Overall, 57{\%} of CIDP patients, 20{\%} of GBS patients, and 2{\%} of control patients had selective, high serum IgM or IgG anti-β-tubulin reactivity. Selective high-titer serum anti-β-tubulin antibodies occur in a majority of patients with CIDP but are rare in other chronic neuropathies or CNS disorders.",
author = "Connolly, {A. M.} and Alan Pestronk and Trotter, {J. L.} and Feldman, {E. L.} and David Cornblath and Olney, {R. K.}",
year = "1993",
language = "English (US)",
volume = "43",
pages = "557--562",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - High–titer selective serum anti–β–tubulin antibodies in chronic inflammatory demyelinating polyneuropathy

AU - Connolly, A. M.

AU - Pestronk, Alan

AU - Trotter, J. L.

AU - Feldman, E. L.

AU - Cornblath, David

AU - Olney, R. K.

PY - 1993

Y1 - 1993

N2 - Although chronic inflammatory demyelinating polyneuropathy (CIDP) is presumed to be an autoimmune disorder, no neural antigen has been recognized as an immune target. We found that serum IgM from a patient with CIDP and an IgM paraprotein reacted with a 53-kd protein by Western blot analysis. Amino acid sequence analysis identified this protein as β-tubulin. We then studied sera from 70 CIDP patients, 35 Guillain-Barré syndrome (GBS) patients, and 483 disease (amyotrophic lateral sclerosis, Alzheimer's disease, multiple sclerosis, diabetes, and other polyneuropathies) and normal controls for selective high-titer anti-β-tubulin using ELISA methodology. Forty-two percent (30/70) of patients with CIDP had selective high titer IgM reactivity against β-tubulin; 23% (16/70) had selective high-titer IgG reactivity against β-tubulin. Overall, 57% of CIDP patients, 20% of GBS patients, and 2% of control patients had selective, high serum IgM or IgG anti-β-tubulin reactivity. Selective high-titer serum anti-β-tubulin antibodies occur in a majority of patients with CIDP but are rare in other chronic neuropathies or CNS disorders.

AB - Although chronic inflammatory demyelinating polyneuropathy (CIDP) is presumed to be an autoimmune disorder, no neural antigen has been recognized as an immune target. We found that serum IgM from a patient with CIDP and an IgM paraprotein reacted with a 53-kd protein by Western blot analysis. Amino acid sequence analysis identified this protein as β-tubulin. We then studied sera from 70 CIDP patients, 35 Guillain-Barré syndrome (GBS) patients, and 483 disease (amyotrophic lateral sclerosis, Alzheimer's disease, multiple sclerosis, diabetes, and other polyneuropathies) and normal controls for selective high-titer anti-β-tubulin using ELISA methodology. Forty-two percent (30/70) of patients with CIDP had selective high titer IgM reactivity against β-tubulin; 23% (16/70) had selective high-titer IgG reactivity against β-tubulin. Overall, 57% of CIDP patients, 20% of GBS patients, and 2% of control patients had selective, high serum IgM or IgG anti-β-tubulin reactivity. Selective high-titer serum anti-β-tubulin antibodies occur in a majority of patients with CIDP but are rare in other chronic neuropathies or CNS disorders.

UR - http://www.scopus.com/inward/record.url?scp=0027465717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027465717&partnerID=8YFLogxK

M3 - Article

C2 - 8451001

AN - SCOPUS:0027465717

VL - 43

SP - 557

EP - 562

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 3

ER -